Phospho-AKT (Ser473) Western Blot Dose-Response to PI3K Inhibitor GDC-0941 in PTEN-Null PC-3 Prostate Cancer Cells

Six GDC-0941 concentrations (0, 0.03, 0.1, 0.3, 1, 3 µM) plus a DMSO vehicle control, each in n=3 independent biological replicates (separate passages/platings on separate days). Cells are treated for a fixed 1 h at 37 °C (chosen to capture proximal phospho-signaling before transcriptional adaptation). Treatment order on the plate is randomized across replicates to avoid edge/position bias. Lanes are loaded at a fixed 20 µg total protein. A single-blind design is used: the analyst quantifying band densities is blinded to lane identity via coded gel images.

BSL-2 for PC-3 human tumor cells; work in a Class II biosafety cabinet. GDC-0941 and DMSO are handled with nitrile gloves; DMSO is a skin-penetration enhancer—avoid co-contact with compounds. Acrylamide gels are precast (no monomer handling), but methanol (transfer buffer) and RIPA detergents require chemical gloves and eye protection. Collect liquid cell waste in 10% bleach for 30 min before disposal; solid biohazard waste autoclaved. ECL and HRP reagents are non-hazardous but handle per SDS.

Vehicle control = 0.1% DMSO (defines 100% phospho-AKT baseline). Positive inhibition control = 3 µM GDC-0941 (expected maximal suppression). Loading control = GAPDH on every membrane. Total AKT serves as the normalization target to distinguish phospho-changes from protein-level changes. An untreated, serum-starved well (0.1% FBS, 16 h) is included as a low-signal reference to confirm assay dynamic range. A no-primary-antibody membrane confirms secondary-antibody specificity.

A monotonic decrease in normalized p-AKT/AKT ratio with increasing GDC-0941. Vehicle = 1.0 (normalized); ~50% suppression near 0.1-0.3 µM; >90% suppression at 3 µM. Total AKT and GAPDH should vary <15% across lanes. A four-parameter logistic fit should yield a cellular IC50 of roughly 0.1-0.5 µM with R^2 > 0.95 and a Hill slope near -1.

• PC-3 cells (ATCC CRL-1435), PTEN-null prostate adenocarcinoma
• RPMI-1640 with L-glutamine + 10% FBS + 1% penicillin/streptomycin
• GDC-0941 (pictilisib), 10 mM stock in DMSO, stored -20 °C
• DMSO (cell-culture grade) for vehicle, final 0.1% v/v in all wells
• RIPA lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS)
• Halt protease + phosphatase inhibitor cocktail (100x), added fresh
• BCA protein assay kit
• 4-12% Bis-Tris precast polyacrylamide gels, MOPS-SDS running buffer
• PVDF membrane (0.45 µm), methanol-activated
• Anti-phospho-AKT (Ser473) (D9E) rabbit mAb, 1:2000
• Anti-AKT (pan) (C67E7) rabbit mAb, 1:1000
• Anti-GAPDH (D16H11) rabbit mAb, 1:5000
• HRP-conjugated anti-rabbit IgG, 1:5000
• ECL substrate, Intercept (TBS) blocking buffer

To establish a quantitative, reproducible immunoblot workflow that measures phospho-AKT (Ser473) and total AKT across a half-log GDC-0941 concentration series in PC-3 prostate cancer cells, enabling calculation of a cellular IC50 for PI3K pathway suppression and normalization of phospho-signal to total protein. The assay serves as the primary pharmacodynamic readout linking compound exposure to on-target node inhibition.

1. Seed PC-3 cells at 3 x 10^5 cells/well in 6-well plates in 2 mL complete RPMI; incubate 24 h to ~70% confluence.
2. Prepare GDC-0941 dilutions in complete medium so the final DMSO is 0.1% in every well including vehicle.
3. Aspirate medium, add 2 mL of each treatment, incubate exactly 60 min at 37 °C / 5% CO2.
4. Place plates on ice, aspirate medium, wash once with 2 mL ice-cold PBS.
5. Add 120 µL ice-cold RIPA + inhibitors per well; scrape, transfer to tubes, rotate 30 min at 4 °C.
6. Centrifuge 14,000 x g, 15 min, 4 °C; collect supernatant. Quantify by BCA.
7. Normalize to 1 µg/µL, add 4x LDS sample buffer + 10x reducing agent, heat 70 °C for 10 min.
8. Load 20 µg/lane; run 4-12% gel at 150 V for 60 min in MOPS buffer.
9. Wet-transfer to PVDF at 100 V for 90 min at 4 °C.
10. Block 1 h RT in Intercept buffer; incubate primary (p-AKT) overnight at 4 °C.
11. Wash 3x 5 min TBST, incubate HRP secondary 1 h RT, wash 3x, image with ECL.
12. Strip or use a replicate membrane; reprobe for total AKT then GAPDH.

Independent variable: GDC-0941 concentration (0-3 µM, 6 levels). Dependent variable: phospho-AKT (Ser473) band intensity normalized to total AKT. Controlled variables: treatment time (60 min), cell passage range (P5-P20), confluence (~70%), total protein loaded (20 µg), DMSO concentration (0.1%), transfer/exposure parameters, and antibody lots (single lot per experiment series).

Because PC-3 cells are PTEN-null and exhibit constitutive PI3K/AKT pathway activation, we hypothesize that GDC-0941 will reduce phospho-AKT (Ser473) in a monotonic, dose-dependent manner with a cellular IC50 in the 0.1-1 µM range, while total AKT remains unchanged. We predict near-complete (>90%) suppression of phospho-AKT at 3 µM with no change to the GAPDH loading control.

Acquire 16-bit TIFF images on a digital imager kept within the linear dynamic range (no saturated pixels). Quantify band density in Image Studio Lite or ImageJ/Fiji using local background subtraction. Compute p-AKT/total-AKT per lane, then express each as a percentage of the within-replicate vehicle. Pool the three biological replicates and fit percent inhibition vs log[GDC-0941] to a four-parameter logistic curve in GraphPad Prism to extract IC50 and Hill slope.

1. No/weak p-AKT signal: confirm phosphatase inhibitors were fresh and lysates kept cold; serum-starvation may have lowered baseline—use 10% FBS. 2. High background/blotchy membrane: increase wash steps to 4x 5 min, filter blocking buffer, ensure even membrane wetting. 3. Non-monotonic dose-response: check pipetting of the dilution series and verify DMSO is constant at 0.1%. 4. Total AKT also decreases: 60 min is too short for protein loss—suspect uneven loading; recheck BCA and reload. 5. Saturated bands: reduce exposure time or load 10 µg; saturation invalidates densitometry.

n=3 biological replicates per concentration. Compare normalized p-AKT across concentrations by one-way ANOVA with Dunnett's post hoc test versus vehicle (alpha = 0.05). IC50 is reported with 95% confidence interval from the nonlinear fit. A priori power analysis (G*Power) for one-way ANOVA with f=0.8, alpha=0.05, power=0.8 supports n=3 across 6 groups for detecting the expected large effect; report exact p-values and effect sizes (eta-squared).